As biologics, biomarker-enriched trials and real-world evidence reshape the COPD landscape, sponsors face both new opportunities and increasing complexity. Success depends on translating these advances into effective cli...
Biotech
Developing transformative therapies with small & mid-sized biopharma companies requires a flexible approach
PlayFrom here to where?
Plotting a course to bring APAC-developed drugs to the world
Download Global and China biotech survey reports
Two new survey reports of 260+ Global and China-based biotech leaders are ready to download.
Driving biotech success at every milestone
Biotech companies are pioneering the future of medicine from genomic breakthroughs to first-in-class immunotherapies. With focused pipelines and bold ambitions, many biotechs operate without the full infrastructure of larger organizations, making speed, precision, and strategic support essential.
ICON delivers the expertise, technology, and global reach to turn biotech innovation into impact. Our empowered structure enables fast decision-making and flexible engagement, backed by the scale of one of the world’s most innovative CROs.
Our dedicated biotech teams are built to understand your unique pressures and priorities, collaborating closely, sharing ownership, and delivering results at every stage of development.
Our four-pillar approach, Patients, People, Process, and Partnership, is designed to transform biotech ambition into real-world impact. By combining patient-centric strategies, expert talent, streamlined operations, and collaborative engagement, ICON empowers you to deliver life-changing therapies faster.
Emerging biotech funding
As new funding models and investor priorities reshape the biotech landscape, companies must navigate a dynamic environment with agility and foresight to secure the capital needed for innovation.
Behind Biotech
Our experts bring more than scientific knowledge - they bring purpose, perspective, and a commitment to partnership.
Partnering with biotechs to transform ideas into life-changing therapies.
ICON provides end-to-end capabilities, from early-phase design to market access; ensuring agility, scalability, and scientific excellence throughout the development journey.
-
Тailored clinical development
8,000 professionals dedicated to biotech delivering agile, customized solutions built around your needs.
-
Consulting and advisory services
Strategic guidance from early development through to commercialization.
-
Therapeutic expertise
Deep experience across therapeutic areas, from first-in-human to late-phase trials.
-
Tools and technologies
Innovative platforms that accelerate research and enhance data-driven decisions.
Emerging biotech, empowered for investment
ICON partners with biotech innovators to sharpen funding strategies, align with investor expectations, and drive value across every stage of development.
Optimising biotech funding whitepaper series
In this two-part whitepaper series on biotech funding, we firstly share insights on how biotechs can secure funding in a highly competitive market, and then shed light on the opportunities available to utilise these funds more effectively and efficiently.
Early phase challenges for biotechs
This whitepaper explores the growing challenges facing biotech during early phase drug development, and how these can be navigated to ensure the best possible outcomes.
Case studies
Explore our biotech case study library showcasing real-world success stories where bold ambition meets ICON’s expertise.
Empowering biotech innovation at every stage of development.
Through advanced analytics, global trial expertise, and strategic partnerships, ICON enables biotechs to streamline processes and achieve faster, smarter outcomes.
Early, precise and efficient
The methods and technologies advancing Alzheimer’s and Parkinson’s R&D
In this CNS whitepaper, which includes extracts from our survey of over 120 neurodegenerative therapeutic developers, we examine how innovative methodologies and technologies are being implemented to improve the success rate of clinical trials across a range of neurodegenerative disorders.
Procedural and regulatory know-how for China biotech in the EU
How to navigate EU MAA regulations and registration
Learn how to navigate the European Medicines Agency registration and regulation procedures and gain access to a potential patient pool of 500 million people.
2023 biotech sector survey
The biotech industry stands at a pivotal moment, navigating funding challenges with resilience and adaptability. After a period of remarkable growth and investment, the landscape shifted abruptly in 2022, and 2023 continued to present its own set of challenges.
De-risking clinical development of precision medicines in oncology
This whitepaper reviews the most pressing challenges and opportunities facing the oncology therapeutic landscape in the emerging era of precision medicine, and reports on how those opportunities and challenges vary by organisational size and region.
Digital disruption
The clinical research industry is making strides in technological innovation, with small but steady increases to the percentage of companies implementing and piloting digital technologies. However, our 2024 digital disruption survey conducted with Citeline shows a slower pace of innovation than predicted by the 2019 survey. Why is this the case?
Obesity and beyond
Embracing multi-indication potential during clinical development
This whitepaper explores the strategic rise of multi-indication drug development for obesity and its comorbidities, offering insights into clinical trial design, regulatory pathways, and commercial opportunities based on recent industry trends and survey data.
.jpeg?crop=yes&w=1017&h=1017&a=325,0&itok=ZQ_TVcyw "obesity_scan_icons"){kind=icon}
Building strong foundations: regulatory insights for biotechs.
Through early engagement strategies, deep procedural expertise, and global regulatory insight, ICON equips biotechs to anticipate challenges, streamline submissions, and accelerate access to key markets worldwide.
Early engagement and regulatory considerations for biotech
Gain insight into the common questions small and emerging biotech companies face, and the importance of early engagement and regulatory affairs when developing an asset and considering a drug development partner.
Biotech blogs and media contributions
-
Media article: 2025 in Review: Global biotech and funding trends
In this interview, Deepali Suri, President of ICON Biotech, breaks down the key trends shaping today’s biotech industry and their global impact. Using insights from ICON’s global and China biotech surveys, capturing input from more than 260 biotech leaders worldwide, Suri highlights emerging therapeutic innovations, the growing influence of AI in R&D, and how geopolitical tensions are redefining international drug development strategies.
-
Media article: The formula for biotech success in 2026: Confidence, resilience and funding
For biotech companies the past two years have been challenging. In 2025 ICON Biotech conducted a follow-up survey of biotech leaders, previously carried out in 2023. The new results show changing trends in the risks, challenges and opportunities in the biotech sector.
-
Blog: Enabling Innovation
Yao Zhong, ICON China Mainland and Hong Kong, is sharing some of the findings from the 2025 China biotech sector survey report. Read more on how a strategic partnership fuels global ambition.
-
Blog: The current landscape of oncology R&D
The panelists discussed promising scientific and strategic pathways in oncology, including next-generation therapeutic modalities, precision trial strategies, AI applications with demonstrated and measurable impact, regulatory and market readiness, and collaborative models for accelerating early-phase oncology programs.
-
Blog: Bring in the biotechs
When Deepali Suri stepped into her new role as president of ICON’s biotech division in September 2025, she brought with her more than two decades of experience across big pharma, biotech, and CROs. She also brought a clear vision for the industry’s future. Read to learn more.
-
Media article: Enabling Innovation: How China-based biotechs are shaping global drug development
Yao Zhong, ICON China Mainland and Hong Kong, is sharing some of the findings from the 2025 China biotech sector survey report. Read more on how a strategic partnership fuels global ambition.
-
Media article: Next-generation modalities, precision trials, and AI-driven breakthroughs in oncology
The panelists discussed promising scientific and strategic pathways in oncology, including next-generation therapeutic modalities, precision trial strategies, AI applications with demonstrated and measurable impact, regulatory and market readiness, and collaborative models for accelerating early-phase oncology programs.
-
Media article: Bring In The Biotechs: ICON’s new biotech President, Deepali Suri, shares her vision for 2026 and beyond
When Deepali Suri stepped into her new role as president of ICON’s biotech division in September 2025, she brought with her more than two decades of experience across big pharma, biotech, and CROs. She also brought a clear vision for the industry’s future. Read to learn more.
Start the conversation
Start the conversation with our biotech team to explore how ICON can accelerate your clinical development and deliver investor-ready trial strategies tailored to your goals.
